Skip to main content

Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 11, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with reduced survival among patients with advanced colorectal, gastroesophageal, and pancreatic cancers, according to a study published online Sept. 5 in the Journal of the National Comprehensive Cancer Network.

Chengwei Peng, M.D., from New York University in New York City, and colleagues queried a real-world database for patients with advanced colorectal, gastroesophageal, and pancreatic cancers (8,670, 1,481, and 1,614 patients, respectively) who received first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens to examine whether omission of the 5-FU bolus is associated with a difference in survival and toxicity.

Overall, 86.3 and 13.7 percent of patients received and did not receive a 5-FU bolus, respectively. The researchers found that omitting the bolus was not associated with a reduction in overall survival after inverse probability of treatment-weighted analysis. However, there were significant associations for bolus omission with reductions in neutropenia (10.7 versus 22.7 percent), thrombocytopenia (11.2 versus 16.1 percent), and use of granulocyte colony-stimulating factor (19.6 versus 29.1 percent) after treatment.

"Our data suggest that omitting the 5-FU bolus may lead to reduced treatment toxicity without compromising efficacy. Future prospective studies are needed to confirm these findings, especially applicability to the adjuvant setting," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

More Than One-Third Have ED Visit Within 90 Days Before Cancer Diagnosis

MONDAY, Nov. 4, 2024 -- More than one-third of patients have emergency department use within 90 days before a confirmed cancer diagnosis, according to a study published online...

Uninsurance Plays Major Role in Racial Disparities Seen in Cancer Diagnosis

FRIDAY, Nov. 1, 2024 -- Lack of health insurance coverage accounts for a considerable proportion of racial and ethnic disparities in advanced-stage diagnoses of cancer, according...

ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer

FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.